ClinicalTrials.Veeva

Menu

Neurofeedback Intervention for Preclinical Alzheimer's Disease

X

XuanwuH 2

Status

Completed

Conditions

Alzheimer Disease
Neurofeedback
Electroencephalogram
Subjective Cognitive Decline

Treatments

Behavioral: Electroencephalogram-based neurofeedback

Study type

Interventional

Funder types

Other

Identifiers

NCT04300933
HanYingsc3

Details and patient eligibility

About

Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective pharmacologic therapy for this disease. Electroencephalogram-based neurofeedback is considered as a potentially treatment strategy. In this project, the investigators aim to investigate the effectiveness of neurofeedback therapy on cognition for individuals with subjective cognitive decline (SCD). Participants will receive electroencephalogram-based neurofeedback therapy once a day for successive five days. Then, the investigators will evaluate the changes of memory function between baseline and post-therapy visits.

Full description

Currently, there has been no effective therapy for Alzheimer's disease (AD). Electroencephalogram-based neurofeedback is now considered as a potentially intervention and may positively affect cognitive function for patients with AD. However, there are few existing studies involving the role of neurofeedback on cognition for subjective cognitive decline (SCD).

Fifty participants with SCD will be recruited in this clinical trial. At baseline, neuropsychological tests are conducted. Participants will receive electroencephalogram-based neurofeedback therapy once a day for successive five days. After that, the investigators will evaluate the changes of memory measures, which is the primary outcome.

Enrollment

50 patients

Sex

All

Ages

50 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 50-79 years old, right-handed and Mandarin-speaking subjects;
  • self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event;
  • normal age-adjusted, gender-adjusted and education-adjusted performance on standardised cognitive tests;
  • concerns (worries) associated with memory complaint;
  • failure to meet the criteria for MCI or dementia

Exclusion criteria

  • a history of stroke;
  • major depression (Hamilton Depression Rating Scale score > 24 points);
  • other central nervous system diseases that may cause cognitive impairment, such as Parkinson's disease, tumors, encephalitis and epilepsy;
  • cognitive impairment caused by traumatic brain injury;
  • systemic diseases, such as thyroid dysfunction, syphilis and HIV;
  • a history of psychosis or congenital mental growth retardation.

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

50 participants in 1 patient group

Neurofeedback therapy
Experimental group
Description:
Fifty participants conduct neurofeedback daily for 5 days.
Treatment:
Behavioral: Electroencephalogram-based neurofeedback

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems